Compare Quest Diagnostics Inc (DGX) vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 (USOI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? Quest Diagnostics Inc trades at $236.29 (market cap $26.24B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $44.84. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 nearer its low. Which is the better fit depends on your goals.
| DGX | USOI | |
|---|---|---|
Market Cap | $26.24B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $238.50 | $61.17 |
52-Week Low | $173.49 | $42.27 |
Enterprise Value | $32.00B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $236.04, down 0.61% on the day, as the stock consolidates near recent highs following strong Q2 2026 earnings. The company has delivered three consecutive quarterly earnings beats, with Q2 EPS of $3.12 exceeding expectations by 10.6%. Revenue growth accelerated to 10.2% year-over-year, supported by strong testing demand and strategic partnerships. Technical indicators show a bullish trend with the stock trading near pivot point resistance at $238.
The outlook remains positive with raised 2026 guidance and consistent dividend payments, though valuation multiples appear full at 25.2x P/E. Key risks include margin pressure from lower-margin contracts and rising project costs. Analyst consensus leans bullish with a $249.50 price target representing 5.7% upside potential from current levels.
USOI trades at $45.66, up 0.09% today, with a bullish technical signal from moving averages and oscillators. The stock shows strong momentum with an ADX of 49.32 indicating a strong trend, though RSI levels suggest potential overbought conditions. Recent news highlights its unique structure as a covered call ETN offering high yield, attracting investor attention for dividend growth strategies in 2026.
Outlook remains positive due to technical strength and high-yield appeal, but risks include reliance on oil price volatility and ETN structure complexities. Investors should weigh the bullish indicators against fundamental opacity and market sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037
USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →
